Financial

Qool Therapeutics Raises $8 Million for Targeted Temperature Management System

MENLO PARK, Calif.–(BUSINESS WIRE)–Qool Therapeutics, Inc., a company developing a novel non-invasive targeted temperature management system, has raised an $8 million Series A-1 round for clinical product development and to prepare for first-in-human studies. The funding was provided by Zhongji Holdings LTD/Join Medical Technology, TAMCAP LLC, BrilliMedical International Corp., BioPacific […]

CHF Solutions, Inc. Announces Closing of $18.0 Million Underwritten Public Offering

EDEN PRAIRIE, Minn., Nov. 27, 2017 (GLOBE NEWSWIRE) — CHF Solutions, Inc. (NASDAQ:CHFS) announced today the closing of an underwritten public offering of Series F convertible preferred stock, together with warrants, for gross proceeds of $18.0 million, prior to deducting underwriting discounts and commissions and offering expenses payable by CHF […]

Opsens’ Japanese partner Zeon medical proceeds with Conversion of US$2 million Debenture

QUEBEC CITY, Nov. 27, 2017 /CNW Telbec/ – Opsens Inc. (“Opsens” or the “Company”) (TSX: OPS) (OTCQX: OPSSF) is pleased to announce the conversion of the US$2 million debenture held by Zeon Medical Inc. (“Zeon Medical”), Opsens’ Japanese partner. Zeon Medical has been a client of Opsens since 2004. In 2012, Opsens granted Zeon Medical the exclusive distribution […]

Boston Scientific To Participate In Citi 2017 Global Healthcare Conference

MARLBOROUGH, Mass., Nov. 27, 2017 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) will participate in the Citi 2017 Global Healthcare Conference on December 7, 2017 in New York. Kevin Ballinger, executive vice president and president, interventional cardiology, and Susie Lisa, vice president, investor relations, will participate in a 40-minute question-and-answer session with the host analyst beginning at approximately 8:45 […]

CHF Solutions Prices $18M Offering

EDEN PRAIRIE, Minn., Nov. 22, 2017 (GLOBE NEWSWIRE) — CHF Solutions(NASDAQ:CHFS) announced today the pricing of an underwritten public offering of Series F convertible preferred stock, together with warrants, for gross proceeds of $18.0 million, prior to deducting underwriting discounts and commissions and offering expenses payable by CHF Solutions. The Series F […]

LivaNova Enters into Binding Letter of Intent to Sell its Cardiac Rhythm Management Business Franchise to MicroPort Scientific Corporation for $190 Million

LONDON & SHANGHAI–(BUSINESS WIRE)–LivaNova PLC (NASDAQ:LIVN) (“LivaNova”) and MicroPort Scientific Corporation (HK:00853) (“MicroPort”) today announced that the companies have entered into a binding Letter of Intent (“LOI”) for the sale of LivaNova’s Cardiac Rhythm Management (“CRM”) Business Franchise to MicroPort for $190 million in cash. The CRM Business Franchise develops, […]

Neovasc Closes Offering of Units Consisting of Common Shares and Warrants and Concurrent Private Placement of Notes and Warrants

VANCOUVER, Nov. 17, 2017 /PRNewswire/ – Neovasc Inc. (NASDAQ, TSX: NVCN) is pleased to announce the closing of its previously announced underwritten offering of 6,609,588 Series A units (the “Series A Units”) and 19,066,780 Series B units (the “Series B Units” and together with the Series A Units, the “Units”) of the […]

Neovasc Announces Results for the Third Quarter of 2017

VANCOUVER, Nov. 14, 2017 /PRNewswire/ – Neovasc Inc. (NASDAQ, TSX: NVCN) today announced financial results for the third quarter ended September 30, 2017 (all figures in U.S. dollars unless otherwise indicated). “From a product perspective, our two lead devices continue to perform well, quarter after quarter; patient after patient,” commented Neovasc CEO, […]